You are here

Our science / Clinical Trials / Find a Trial / NCT00167999

Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units

Back to Search Print Save as PDF Bookmark Trial

NCT00167999

Last updated on April 11, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Seoul, , 133-792 Korea, Republic of
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Gram-Positive Bacterial Infections, Escherichia Coli Infections, Klebsiella Infections
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
15+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Eligible patients of either sex, 15 years of age or older

- Patients who are admitted to the department of hematology and oncology

- Provide written informed consent

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients who have hypersensitivity to ?-lactam antibiotics

- Female who are pregnant or breast-feeding

- Any underlying conditions or non-infectious diseases that will be ultimately fatal
within 30 days

NCT00167999
Pfizer
Completed
Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Ulcerative Colitis
A Clinical Study of PF-06480605 for the Treatment of Moderate to Severe Ulcerative Colitis. (TUSCANY, B7541002)
NCT02840721
All Genders
18+
Years
Multiple Sites
Ulcerative Colitis
Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis
NCT01470612
All Genders
18+
Years
Multiple Sites
Meningococcal Infections
Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary Vaccination
NCT01934140
All Genders
17+
Years
Multiple Sites
Meningococcal Infections
Persistence of Antibodies After Meningococcal Vaccine PF-06866681 in Healthy Children
NCT01900899
All Genders
0+
Years
Multiple Sites
Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units
Effects of Piperacillin-Tazobactam Use on the Prevalence Rate of Extended-Spectrum Beta-Lactamase (ESBL) Producing Escherichia Coli and Klebsiella Pneumoniae in Hematology and Oncology Units.
To determine the value of increasing use of piperacillin/tazobactam as empiric therapy and restricting extended-spectrum cephalosporins in reducing the cases of ESBL producing Escherichia coli and Klebsiella pneumoniae in hematology and oncology units
Not Provided
Observational
Observational Model: Case Control
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Prospective
Not Provided
Not Provided
Not Provided
Not Provided
  • Gram-Positive Bacterial Infections
  • Escherichia Coli Infections
  • Klebsiella Infections
Drug: piperacillin-tazobactam
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
200
Not Provided
Not Provided

Inclusion Criteria:

  • Eligible patients of either sex, 15 years of age or older
  • Patients who are admitted to the department of hematology and oncology
  • Provide written informed consent

Exclusion Criteria:

  • Patients who have hypersensitivity to ?-lactam antibiotics
  • Female who are pregnant or breast-feeding
  • Any underlying conditions or non-infectious diseases that will be ultimately fatal within 30 days
Sexes Eligible for Study: All
15 Years and older   (Child, Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Korea, Republic of
 
 
NCT00167999
0910X-101676
Not Provided
Not Provided
Not Provided
Not Provided
Wyeth is now a wholly owned subsidiary of Pfizer
Not Provided
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
Wyeth is now a wholly owned subsidiary of Pfizer
March 2007

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now